TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of$ 0.30. This compares to loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.67%. A quarter ago, it was expected that this company would post a loss of$ 0.25 per share when it actually produced a loss of $0.32, delivering a surprise of -28%. Over the last four quarters, the company has ...